

Keyword Index Volume 28 (2016)

ADRs	13	health system	221
adverse drug reaction	25	heart failure	181
Adverse drug reactions (ADRs)	115		
adverse events	101, 163	imipramine	143
analgesic nephropathy	189	immunogenicity	45
analgesics	189	independent	221
animal studies	1	interchangeability	45
antidepressants	125	Iran	25
antidiabetic drugs	197		
antiretroviral agents	13	key-opinion-leaders	33
attitude	25	knowledge	25
Autism spectrum disorder	125		
		length of stay	181
bias	221	long lasting harm	1
biologics	45		
biosimilars	45	market discontinuations	197
		measurement/epidemiology	163
chronic renal impairment	189	medical education	61
citalopram	33	medical error	93, 163
clinical trial methodology	101	medical malpractice	213
Cochrane	221	medication errors	77
conflicts of interest	221	medicine information	221
		morbidity and mortality meeting	65
defensive medicine	213		
depression	33, 143	NAFDAC	13
disclosure	93	neurodevelopmental delay	125
drug approvals	197	neurodevelopmental spectrum disorders	125
drug promotion	221	Nigeria	77
drug safety	101, 197	non-steroidal anti-inflammatory agents	181
education	65	obligation	93
efficacy	45	office staff	61
epidemiology and detection	163	orthopaedic surgery	65
escitalopram	33		
ethical standards	221	paroxetine	143
evidence	221	patient relationships	61
extrapolation	45	patient safety incidents	65
		patient safety	65, 163
FDA	33, 197	permanent sexual dysfunction	1
		pharmaceutical policy	221
general practitioners	25	pharmacovigilance	13, 115
ghostwriting	33	post marketing drug safety	115
		practice	25
health care costs	213	pregnancy	125
health professionals	77	psychiatric litigation	33
		psychotropic drugs	101

relapse	143	serotonin reuptake inhibitors	125
reporting	25	signals	13, 115
research misconduct	33	SSRI antidepressants	33
risk management	163	SSRIs	143
Russia	221	systematic review	1
safety culture	163	taper phase	143
safety	45	tort reform	213
selective serotonin reuptake inhibitors (SSRIs)	1		